Study showed 40 percent reduction of the degree of myocardial damage during percutaneous coronary intervention compared to standard care which translated into better outcomes after 30 days in patients treated in the experimental arm versus the conventional one.
Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.
No such practice currently exists for anti-platelet agents. Current treatment strategies for patients with coronary artery disease ignore the individual response to antiplatelet agent(s), and likewise fail to identify therapeutic targets for platelet reactivity necessary to evaluate the intensity of treatment.
Yet, inhibition of platelet aggregation following standard oral antiplatelet agents (i.e. aspirin or clopidogrel), has limited data from dedicated trials addressing the long-term safety and efficacy of DES in high-risk subgroups like diabetics, and patients with ST and non ST segment elevation MI or complex lesions. Reaction vary greatly among healthy subjects and patients. Many previous studies have shown that poor response to oral antiplatelet agents increases 1.8-10-fold, the risk of thrombotic events, including myocardial infarction, particularly after coronary angioplasty.
It is unknown whether this reflects suboptimal platelet inhibition per se which might benefit from alternative/more potent antiplatelet agents. Studies aiming at improving outcomes while intensifying platelet inhibition in these patients who are poor responders to standard oral antiplatelet gents are critical to establishing a causal relationship between poor response to a standard anti-platelet regimen and worse outcome. This may help identifying patients who are at high risk for cardiovascular recurrences because they are not fully protected by standard medications. In these patients, the tailored use of alternative anti-platelet agents may provide better protection from cardiovascular complications.
We selected patients, based on results of a point-of-care assay (VerifyNow produced by Accumetrics, Inc., San Diego, CA, USA), undergoing elective percutaneous coronary intervention who were presenting with suboptimal response to either aspirin and/or clopidogrel (these two medications together are crucial to make percutaneous coronary intervention both effective and safe). Poor responders to either aspirin and/or clopidogrel were then randomly treated with standard care (placebo on top of aspirin and clopidogrel) or with the addition of a potent intravenous antiplatelet agents (tirofiban).
Neither the patients nor their doctors knew whether they were receiving the real or placebo treatment. We were primarily interested in evaluating the effect of treatment on the incidence of myocardial damage induced during percutaneous coronary intervention (periprocedural myocardial infarction). We showed that intensifying platelet inhibition with tailored infusion of tirofiban in this population results in a greater than 40 percent reduction of the degree of myocardial damage during percutaneous coronary intervention compared to standard care which translated into a better outcomes a 30 days in patients treated in the experimental arm versus the conventional one. Both patients being poor responsive to aspirin or to clopidogrel seem to derive the same benefit.
Jacqueline Partarrieu | alfa
Innovative genetic tests for children with developmental disorders and epilepsy
11.07.2018 | Christian-Albrechts-Universität zu Kiel
Oxygen loss in the coastal Baltic Sea is “unprecedentedly severe”
05.07.2018 | European Geosciences Union
For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.
To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...
For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.
Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...
Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.
A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...
Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.
"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....
Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.
Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...
13.07.2018 | Event News
12.07.2018 | Event News
03.07.2018 | Event News
16.07.2018 | Physics and Astronomy
16.07.2018 | Transportation and Logistics
16.07.2018 | Agricultural and Forestry Science